ransporter-2 (SGLT-2) inhibitor or a glucagon like
peptide 1 receptor agonist with demonstrated cardiovascular disease beneﬁt should be considered, irrespective of the blood glucose level.
SGLT-2 inhibitors should not be started in drug naïve
people with a diabetes related foot ulcer or gangrene
and temporary discontinuation should be considered in
people already using these drugs, until the affected foot
is healed.
Grade

Certainty of evidence

Best